glp 1 non responders Not losing weight on Ozempic, Wegovy or Mounjaro? You're not the only one. GLP-1 weight loss medications can be incredibly helpful for some people. But they don't work the same way for Unfortunately up to 20% of

You know what could be driving it

Still, insurance coverage and cost considerations mean both drugs remain relevant, and patient-centred conversations about therapy choice are critical. GLP-1s beyond weight loss as multi-system therapies Liver disease and metabolic steatohepatitis Non-alcoholic fatty liver disease (NAFLD) and the more severe metabolic dysfunction-associated steatohepatitis (MASH) have few effective pharmacologic treatments

Amblard, M., Fehrentz, J

Mouth closed

Even patients with coverage often face high copays ($200-$500 monthly) because insurers place these drugs in the highest cost-sharing tiers

Ethics declarations Author taxonomy FA, PCS, MM Conceptualization